These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8933296)

  • 41. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
    Janicak PG; Glick ID; Marder SR; Crandall DT; McQuade RD; Marcus RN; Eudicone JM; Assunção-Talbott S
    J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma haloperidol levels and clinical response.
    Smith RC
    Arch Gen Psychiatry; 1987 Dec; 44(12):1110-2. PubMed ID: 3689100
    [No Abstract]   [Full Text] [Related]  

  • 43. Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach.
    Sauriol L; Laporta M; Edwardes MD; Deslandes M; Ricard N; Suissa S
    Clin Ther; 2001 Jun; 23(6):942-56. PubMed ID: 11440294
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predicting haloperidol treatment response in chronic schizophrenia.
    van Kammen DP; Kelley ME; Yao JK; Gilbertson MW; Gurklis JA; Inosaka T; Saito H; Peters JL; Sato M
    Psychiatry Res; 1996 Aug; 64(1):47-58. PubMed ID: 8888364
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia.
    McCue RE; Waheed R; Urcuyo L; Orendain G; Joseph MD; Charles R; Hasan SM
    Br J Psychiatry; 2006 Nov; 189():433-40. PubMed ID: 17077434
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sexual disturbances during clozapine and haloperidol treatment for schizophrenia.
    Hummer M; Kemmler G; Kurz M; Kurzthaler I; Oberbauer H; Fleischhacker WW
    Am J Psychiatry; 1999 Apr; 156(4):631-3. PubMed ID: 10200746
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Amoxapine as an antipsychotic: comparative study versus haloperidol.
    Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
    J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The relationship of haloperidol concentrations to therapeutic response.
    Perry PJ; Pfohl BM; Kelly MW
    J Clin Psychopharmacol; 1988 Feb; 8(1):38-43. PubMed ID: 3350997
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dose-response relationship of sertindole and haloperidol using the pharmacopsychometric triangle.
    Bech P; Tanghøj P; Andreasson K; Overø KF
    Acta Psychiatr Scand; 2011 Feb; 123(2):154-61. PubMed ID: 20560900
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radio receptor assay of serum neuroleptic levels in psychiatric patients.
    Krska J; Sampath G; Shah A; Soni SD
    Br J Psychiatry; 1986 Feb; 148():187-93. PubMed ID: 2870755
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum haloperidol concentration and clinical response in schizophrenia.
    Kirch DG; Bigelow LB; Korpi ER; Wagner RL; Zalcman S; Wyatt RJ
    Schizophr Bull; 1988; 14(2):283-9. PubMed ID: 3201181
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
    Krakowski MI; Czobor P; Citrome L; Bark N; Cooper TB
    Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
    Tollefson GD; Sanger TM
    Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
    Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
    Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
    J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
    Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
    J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dimensions of the Brief Psychiatric Rating Scale: an examination of stability during haloperidol treatment.
    Czobor P; Volavka J
    Compr Psychiatry; 1996; 37(3):205-15. PubMed ID: 8732588
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasma level monitoring of antipsychotic drugs. Clinical utility.
    Dahl SG
    Clin Pharmacokinet; 1986; 11(1):36-61. PubMed ID: 2868820
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety.
    Davies A; Adena MA; Keks NA; Catts SV; Lambert T; Schweitzer I
    Clin Ther; 1998; 20(1):58-71. PubMed ID: 9522104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.